液体活检赋能膀胱癌全病程精准管理
膀胱癌管理覆盖筛查、诊断、治疗决策与复发监测,传统膀胱镜、影像及病理存在无创动态监测与分子分层局限。尿液液体活检适于筛查、辅助诊断及腔内复发监测,血液液体活检反映系统性肿瘤生物学,在围手术期辅助治疗决策与治疗应答监测有潜在价值。二者优势互补,但临床转化仍面临样本标准化不足、检测体系不统一及成本较高等挑战。
要点
- 尿液液体活检更适于膀胱癌筛查、辅助诊断及腔内复发监测。
- 血液液体活检反映系统性肿瘤生物学,潜在用于围手术期决策与应答监测。
- 临床转化需解决样本标准化、检测体系统一及成本问题。
核心结论
- 液体活检是膀胱癌全病程精准管理的重要补充,尿液与血液途径各有侧重、优势互补。
研究设计与样本
- 本文为综述,围绕膀胱癌筛查、诊断、治疗决策及复发监测全病程,汇总尿液与血液液体活检的应用价值与挑战。
主要发现
- 尿液液体活检因膀胱肿瘤与尿液直接接触,更适用于筛查、辅助诊断及腔内复发监测。
- 血液液体活检能更好地反映肿瘤系统性生物学特征,在围手术期辅助治疗决策和治疗应答监测中具有潜在价值。
- 液体活检临床转化面临样本标准化不足、检测体系尚未统一及成本较高等挑战。
临床怎么用
- 在现有指南路径中明确液体活检的补充定位,优化检测靶标组合并规范检测标准。
- 通过前瞻性研究推动液体活检融入膀胱癌全病程精准管理。
局限性
- 样本标准化不足。
- 检测体系尚未统一。
- 成本较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bladder cancer management encompasses the entire clinical course, including screening, diagnosis, treatment decision-making, and recurrence monitoring. Although conventional approaches based on cystoscopy, imaging, and histopathology remain the foundation of clinical practice, they have limitations in noninvasive dynamic monitoring and molecular stratification. By analyzing tumor-derived cells and molecular information in urine or blood, liquid biopsy provides an important complementary approach for precision management of bladder cancer across the disease course. Owing to the direct contact between bladder tumors and urine, urine-based liquid biopsy is more suitable for screening, adjunctive diagnosis, and intravesical recurrence monitoring. In contrast, blood-based liquid biopsy better reflects systemic tumor biology and has potential value in perioperative adjuvant treatment decision-making and treatment response monitoring. These two approaches have distinct focuses and complementary roles across different disease stages and clinical scenarios. Nevertheless, the clinical translation of liquid biopsy still faces challenges, including insufficient sample standardization, heterogeneous detection systems, and relatively high costs. Future efforts should further define its complementary role within existing guideline-based pathways, optimize biomarker panels, standardize detection procedures, and promote its integration into precision management of bladder cancer through prospective studies. 膀胱癌临床管理贯穿筛查、诊断、治疗决策及复发监测全过程。虽然基于膀胱镜、影像学和组织病理学的诊疗模式是临床实践的基础,但在无创动态监测和分子分层方面仍存在局限。通过分析尿液或血液中肿瘤来源的细胞及分子信息,液体活检为膀胱癌全病程精准管理提供了重要补充。由于膀胱肿瘤与尿液直接接触,尿液液体活检更适用于筛查、辅助诊断及腔内复发监测;相比之下,血液液体活检能更好地反映肿瘤的系统性生物学特征,在围手术期辅助治疗决策和治疗应答监测中具有潜在价值。二者在不同疾病阶段和临床场景中各有侧重、优势互补。与此同时,液体活检临床转化仍面临样本标准化不足、检测体系尚未统一及成本较高等挑战。未来需进一步明确其在现有指南路径中的补充定位,优化检测靶标组合,规范检测标准,并通过前瞻性研究推动其融入膀胱癌全病程精准管理。.
引用
- Zhong WL, Zheng HR, Lin TX, et al. [Liquid biopsy empowers precision medicine across the full course of bladder cancer]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 42203645. doi:10.3760/cma.j.cn112139-20260320-00118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。